NDLI: Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding

Content Provider	Springer Nature : BioMed Central
Author	Vincent, Jean-Louis Rossaint, Rolf Riou, Bruno Ozier, Yves Zideman, David Spahn, Donat R
Abstract	Introduction Our aim was to develop consensus guidelines for use of recombinant activated factor VII (rFVIIa) in massive hemorrhage. Methods A guidelines committee derived the recommendations using clinical trial and case series data identified through searches of available databases. Guidelines were graded on a scale of A to E (with A being the highest) according to the strength of evidence available. Consensus was sought among the committee members for each recommendation. Results A recommendation for the use of rFVIIa in blunt trauma was made (grade B). rFVIIa might also be beneficial in post-partum hemorrhage (grade E), uncontrolled bleeding in surgical patients (grade E), and bleeding after cardiac surgery (grade D). rFVIIa could not be recommended for use in the following: in penetrating trauma (grade B); prophylactically in elective surgery (grade A) or liver surgery (grade B); or in bleeding episodes in patients with Child–Pugh A cirrhosis (grade B). Efficacy of rFVIIa was considered uncertain in bleeding episodes in patients with Child–Pugh B and C cirrhosis (grade C). Monitoring of rFVIIa efficacy should be performed visually and by assessment of transfusion requirements (grade E), while thromboembolic adverse events are a cause for concern. rFVIIa should not be administered to patients considered unsalvageable by the treating medical team. Conclusion There is a rationale for using rFVIIa to treat massive bleeding in certain indications, but only adjunctively to the surgical control of bleeding once conventional therapies have failed. Lack of data from randomized, controlled clinical trials, and possible publication bias of the case series data, limits the strength of the recommendations that can be made.
Related Links	https://ccforum.biomedcentral.com/counter/pdf/10.1186/cc5026.pdf
Ending Page	12
Page Count	12
Starting Page	1
File Format	HTM / HTML
ISSN	13648535
DOI	10.1186/cc5026
Journal	Critical Care
Issue Number	4
Volume Number	10
Language	English
Publisher	BioMed Central
Publisher Date	2006-08-18
Access Restriction	Open
Subject Keyword	Intensive Critical Care Medicine Emergency Medicine Orthotopic Liver Transplantation Blunt Trauma Fresh Freeze Plasma Recombinant Factor VIIa rFVIIa Administration
Content Type	Text
Resource Type	Article
Subject	Critical Care and Intensive Care Medicine
Journal Impact Factor	8.8/2023
5-Year Journal Impact Factor	10.4/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective

Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings

Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials

Regional variation of the off-licence use of rFVIIa for patients with uncontrolled haemorrhage in England

Treatment of obstetric hemorrhage with recombinant activated factor VII

Recombinant activated factor VII for the treatment of bleeding in abdominal surgery and cardiac surgery

Use of recombinant factor VIIa for emergency reversal of anticoagulation

Recombinant activated coagulation factor VII (rFVIIa) as an adjunctive hemostatic therapy in patients with multiple system organ failure and acute upper gastrointestinal bleeding

Freeze dried plasma: a French army specialty

Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective

Similar Documents

Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective

Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings

Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials

Regional variation of the off-licence use of rFVIIa for patients with uncontrolled haemorrhage in England

Treatment of obstetric hemorrhage with recombinant activated factor VII

Recombinant activated factor VII for the treatment of bleeding in abdominal surgery and cardiac surgery

Use of recombinant factor VIIa for emergency reversal of anticoagulation

Recombinant activated coagulation factor VII (rFVIIa) as an adjunctive hemostatic therapy in patients with multiple system organ failure and acute upper gastrointestinal bleeding

Freeze dried plasma: a French army specialty

Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective